Published in Health Business Week, October 21st, 2005
Trading on the TSX will began on September 21, 2005 under the trading symbol NPC.
Gordon McCauley, president and CEO of Allon, said joining the TSX reflects the company's progress as a clinical-stage Canadian biotechnology company developing drugs that protect against conditions such as stroke, traumatic brain injury, Alzheimer disease, multiple sclerosis and neuropathy.
"Our team has consistently added value to Allon's clinical and preclinical portfolio," said McCauley. "We believe our TSX listing reflects this enhanced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week